Infectious Diseases in Obstetrics and Gynecology

Research Article

Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya

Table 3

Association of age and sex-adjusted -scores for weight, weight-for-length, length, and head circumference (HC) among HEU infants and maternal TDF use in pregnancy, by 6-week and 9-month immunization visits¹.


Growth outcome	Infants attending 6-week immunization visit				Infants attending 9-month immunization visit
	⁢Univariate²		⁢Multivariate^2,3		⁢Univariate²		⁢Multivariate^2,3
	Coeff. or OR (crude) (95% CI)	value	Coeff. or OR (adj) (95% CI)	value	Coeff. or OR (crude) (95% CI)	value	Coeff. or OR (adj.) (95% CI)	value

Weight
Absolute WAZ	−0.46 (−0.93, 0.01)	0.056	−0.46 (−0.93, 0.01)	0.057	−0.31 (0.96, 0.34)	0.341	−0.31 (−0.97, 0.35)	0.349
WAZ < −2 SD	1.84 (0.55, 6.23)	0.322	1.86 (0.54, 6.35)	0.321	1.67 (0.59, 4.72)	0.333	1.60 (0.56, 4.56)	0.378
Absolute WLZ	−0.31 (−1.15, 0.53)	0.461	−0.30 (−1.16, 0.56)	0.483	−0.24 (−1.19, 0.71)	0.608	−0.22 (−1.19, 0.76)	0.655
WLZ < −2 SD	0.58 (0.18, 1.93)	0.377	0.59 (0.17, 1.93)	0.374	1.62 (0.46, 5.71)	0.450	1.63 (0.45, 5.94)	0.452

Length
Absolute LAZ	0.02 (−0.81, 0.86)	0.954	−0.00 (−0.83, 0.83)	0.992	−0.15 (−1.17, 0.88)	0.775	−0.35 (−1.40, 0.71)	0.514
LAZ < −2 SD	0.99 (0.49, 1.99)	0.977	1.03 (0.51, 2.06)	0.941	1.64 (0.70, 3.88)	0.255	1.89 (0.80, 4.46)	0.147

Head circumference
Absolute HCZ	−0.04 (−0.77, 0.69)	0.911	−0.02 (−0.76, 0.71)	0.948	−0.06 (−1.07, 0.95)	0.905	−0.07 (−1.04, 0.90)	0.888
HCZ < −2 SD	2.08 (0.27, 15.9)	0.480	2.07 (0.27, 16.06)	0.483	1.33 (0.33, 5.38)	0.686	1.33 (0.33, 5.29)	0.684

SD = Standard deviation.
¹Maternal TDF use defined as any reported TDF-containing ARV regimen used at any time during pregnancy for any amount of time among mothers that used combination ART for HIV treatment or PMTCT while pregnant.
²Logistic regression models for binary outcomes and linear regression for continuous outcomes.
³Adjusted for maternal age, maternal education level, breastfeeding, gestational age at birth, time since maternal HIV diagnosis, maternal WHO clinical stage, timing of ART initiation (before or during pregnancy), trimester of first combo ART regimen use during pregnancy, and PI-containing ART regimen.